• An Allogeneic Cell Therapy Company


PlateletBio is an allogeneic cell therapy biotechnology company with a highly differentiated technological platform that produces cell therapeutics in the form of platelet-like cells (PLCs™) derived from human induced pluripotent stem cells.

The company is developing allogeneic PLCs™ as potential platelet enhancers or replacements for donor platelets in a variety of clinical conditions in which patients are in need of platelets. In parallel, we’re developing genetically engineered PLCs™ that deliver various biological payloads (proteins, cytokines, monoclonal antibodies or nucleic acids) to diseased tissues in vivo as the next generation of cellular therapeutics.

We make PLCs™ in a patented process that mimics the conditions inside bone marrow, where platelets are normally produced.


We begin with induced pluripotent stem cells, which have the ability to develop into almost any kind of tissue in the body. We create megakaryocytes, the progenitor cells within bone marrow that produce platelets.

Inside our patented platelet bioreactor, megakaryocytes are exposed to environmental conditions found inside bone marrow.

These conditions include a permeable membrane through which the cells extend arms similar to proplatelets – as they would extend arms through the walls of blood vessels – and flowing media that generates the shear stresses similar to those found inside a blood vessel. These induce megakaryocytes to begin producing platelet-like cells (PLCs) that are collected for use.

a series of six microscopic images of the PLTs+™ development process
Bioreactor by Platelet BioGenesis


Our scalable megakaryocyte manufacturing platform turns stem cells into megakaryocytes in 14 days.

Our patented bioreactor is designed to be stacked to quickly ramp-up scale production.

And with a grant from the U.S. Department of Defense, we are developing a mobile version of our system.


Our system supports a bold solution to a widespread problem: abundant supplies of lifesaving platelet-like cells (PLCs), where and when they are needed. Furthermore, we are engineering PLCs that can deliver medicines within the body to specific sites of disease.

Our engineered PLCs™ show promise towards becoming a new modality of healthcare with potential to treat aggressive cancers and other life-threatening diseases.

schematic of Platelet BioGenesis patented bioreactor and visualization of production

Benefits of our designer PLCs™

yellow rocket icon

cGMP-compliant, scalable, validated manufacturing process

yellow icon of a puzzle piece in a drop

Designer platelets create a new therapeutic modality

yellow icon of a game plan

PLCs™ are anucleate – fewer clinical and regulatory obstacles

yellow icon of arrows moving from one point out to three others

PLCs™ are immuno-privileged – no required blood type matching